| 1 |
Pérez-gonzález A, Suárez-garcía I, Ocampo A, Poveda E. Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges. Microorganisms 2022;10:433. [DOI: 10.3390/microorganisms10020433] [Reference Citation Analysis]
|
| 2 |
Cheng Z, Lin P, Cheng N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne) 2021;8:713981. [PMID: 34676223 DOI: 10.3389/fmed.2021.713981] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 3 |
Liu Y, Maya S, Ploss A. Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions. Viruses 2021;13:777. [PMID: 33924793 DOI: 10.3390/v13050777] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 4 |
Opaleye OO, Akanbi OA, Osundare FA, Wang B, Adesina O, Oluremi AS, Sunday ST, Akindele AA, Klink P, Bock CT. Prevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigeria. Virol J 2021;18:20. [PMID: 33446224 DOI: 10.1186/s12985-021-01493-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 5 |
Lin L, Li TS. Multidisciplinary collaborative integrated management of increasingly prominent HIV complications in the post-cART era. HIV Med 2020;21:683-91. [PMID: 33369030 DOI: 10.1111/hiv.13022] [Reference Citation Analysis]
|
| 6 |
Lukhwareni A, Gededzha MP, Amponsah-Dacosta E, Blackard JT, Burnett RJ, Selabe SG, Kyaw T, Mphahlele MJ. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans. Viruses 2020;12:E634. [PMID: 32545313 DOI: 10.3390/v12060634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Maponga TG, McNaughton AL, van Schalkwyk M, Hugo S, Nwankwo C, Taljaard J, Mokaya J, Smith DA, van Vuuren C, Goedhals D, Gabriel S, Andersson MI, Preiser W, van Rensburg C, Matthews PC. Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort. J Infect 2020;81:121-30. [PMID: 32360882 DOI: 10.1016/j.jinf.2020.04.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 8 |
Ciccullo A, Baldin G, Borghetti A, Di Giambenedetto S. Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Rev Anti Infect Ther 2020;18:279-92. [PMID: 32067525 DOI: 10.1080/14787210.2020.1729742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 9 |
Yang R, Gui X, Ke H, Xiong Y, Gao S. Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese. J Viral Hepat 2020;27:127-34. [PMID: 31571343 DOI: 10.1111/jvh.13212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 10 |
Maponga TG, Mcnaughton AL, Van Schalkwyk M, Hugo S, Nwankwo C, Taljaard J, Mokaya J, Smith DA, van Vuuren C, Goedhals D, Gabriel S, Andersson MI, Preiser W, van Rensburg C, Matthews PC. Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort.. [DOI: 10.1101/19007963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 11 |
Naing C, Poovorawan Y, Tong KS. Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis. BMC Infect Dis 2018;18:564. [PMID: 30428847 DOI: 10.1186/s12879-018-3506-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 12 |
Kamenya T, Damian DJ, Ngocho JS, Philemon RN, Mahande MJ, Msuya SE. The prevalence of hepatitis B virus among HIV-positive patients at Kilimanjaro Christian Medical Centre Referral Hospital, Northern Tanzania. Pan Afr Med J 2017;28:275. [PMID: 29881515 DOI: 10.11604/pamj.2017.28.275.11926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 13 |
Berto A, Day J, Van Vinh Chau N, Thwaites GE, My NN, Baker S, Darton TC. Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: a systematic review. BMC Infect Dis 2017;17:260. [PMID: 28399806 DOI: 10.1186/s12879-017-2360-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 14 |
Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 15 |
Huang YS, Chang SY, Sheng WH, Sun HY, Lee KY, Chuang YC, Su YC, Liu WC, Hung CC, Chang SC. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. PLoS One 2016;11:e0169228. [PMID: 28033344 DOI: 10.1371/journal.pone.0169228] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 16 |
Li Y, Xie J, Han Y, Wang H, Zhu T, Wang N, Lv W, Guo F, Qiu Z, Li Y, Du S, Song X, Thio CL, Li T. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL. J Acquir Immune Defic Syndr 2016;72:39-45. [PMID: 26745828 DOI: 10.1097/QAI.0000000000000927] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
|
